Redhill Biopharma Ltd
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for … Read more
Redhill Biopharma Ltd - Asset Resilience Ratio
Redhill Biopharma Ltd (RDHL) has an Asset Resilience Ratio of 14.88% as of March 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2010–2024)
This chart shows how Redhill Biopharma Ltd's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Redhill Biopharma Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $2.73 Million | 14.88% |
| Total Liquid Assets | $2.73 Million | 14.88% |
Asset Resilience Insights
- Moderate Liquidity: Redhill Biopharma Ltd has 14.88% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Redhill Biopharma Ltd Industry Peers by Asset Resilience Ratio
Compare Redhill Biopharma Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biostar Pharmaceuticals Inc
PINK:BSPM |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
High Sierra Technologies Inc
PINK:HSTI |
Drug Manufacturers - Specialty & Generic | 0.01% |
|
Dongwha Pharm.Co.Ltd
KO:000020 |
Drug Manufacturers - Specialty & Generic | 1.92% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.46% |
|
Yuhan Corp.
KO:000100 |
Drug Manufacturers - Specialty & Generic | 0.99% |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153 |
Drug Manufacturers - Specialty & Generic | 1.81% |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423 |
Drug Manufacturers - Specialty & Generic | 20.44% |
|
Kotra Industries Bhd
KLSE:0002 |
Drug Manufacturers - Specialty & Generic | 9.82% |
Annual Asset Resilience Ratio for Redhill Biopharma Ltd (2010–2024)
The table below shows the annual Asset Resilience Ratio data for Redhill Biopharma Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 15.16% | $2.73 Million | $18.04 Million | +11.73pp |
| 2023-12-31 | 3.43% | $790.04K | $23.05 Million | +3.42pp |
| 2022-12-31 | 0.01% | $15.00K | $158.87 Million | -4.70pp |
| 2021-12-31 | 4.71% | $8.53 Million | $181.19 Million | +4.43pp |
| 2020-12-31 | 0.28% | $498.00K | $180.24 Million | -25.16pp |
| 2019-12-31 | 25.44% | $18.85 Million | $74.10 Million | -13.31pp |
| 2018-12-31 | 38.74% | $24.18 Million | $62.41 Million | -13.14pp |
| 2017-12-31 | 51.88% | $29.75 Million | $57.34 Million | +35.22pp |
| 2016-12-31 | 16.67% | $12.37 Million | $74.21 Million | -38.13pp |
| 2015-12-31 | 54.80% | $36.62 Million | $66.83 Million | -4.30pp |
| 2014-12-31 | 59.10% | $17.05 Million | $28.86 Million | +57.27pp |
| 2013-12-31 | 1.83% | $262.00K | $14.34 Million | -5.89pp |
| 2012-12-31 | 7.72% | $1.55 Million | $20.10 Million | -14.96pp |
| 2011-12-31 | 22.67% | $4.58 Million | $20.19 Million | +22.53pp |
| 2010-12-31 | 0.14% | $15.00K | $10.51 Million | -- |